Expression of Chemokine Receptors on Th1/Th2 CD4+ Lymphocytes in Patients with Multiple Sclerosis

Alireza Andalib1, Hassan Doulabi, Mohamadreza Najafi

  • 1Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran. Andalib@med.mui.ac.ir

Insights

Interferon-beta therapy shifts T-helper cell balance in Multiple Sclerosis (MS) patients from a Th1 to a Th2 dominant state. Monitoring chemokine receptor expression on CD4 T cells can help evaluate MS disease status.

Area of Science:

  • Immunology
  • Neuroscience
  • Cell Biology

Background:

  • Multiple Sclerosis (MS) is a T-helper 1 (Th1) cell-dependent inflammatory disease of the central nervous system.
  • Th1 cells express CXCR3, CCR5, and CCR6, while Th2 cells express CCR3 and CCR4.
  • Immunomodulatory cytokines can alter chemokine receptor expression patterns on lymphocyte subsets.

Purpose of the Study:

  • To measure chemokine receptor expression on CD4 T cells in Multiple Sclerosis (MS) patients.
  • To evaluate the shift in Th1/Th2 dominance following Interferon-beta (IFN-β) treatment in MS patients.

Main Methods:

  • Flow cytometry was used to detect chemokine receptor expression on CD4 T cells.
  • Peripheral blood mononuclear cells (PBMCs) were analyzed from 26 MS patients before and after IFN-β therapy, and from a healthy control group.

Main Results:

  • MS patients showed altered lymphocyte percentages compared to controls.
  • CD4+CXCR3+ cells were significantly higher in pre-treated MS patients than in healthy controls, decreasing after IFN-β treatment.
  • CD4+CCR4+ cell subsets became dominant after IFN-β therapy, indicating a shift towards a Th2 response.
  • A strong association was found between pre- and post-treatment CXCR3 and CCR4 expression.

Conclusions:

  • IFN-β treatment induces a shift from Th1 to Th2 dominance in MS patients.
  • Chemokine receptor expression patterns on Th1/Th2 cell subsets can serve as a biomarker for monitoring MS disease status and treatment efficacy.
Abstract